FIBRONOSTICS

Contact Us
Portal Login

Application of LIVERFASt to Predict Steatosis in Chronic Hepatitis B Patients with Metabolic Syndrome

Application of LIVERFASt to Predict Steatosis in Chronic Hepatitis B Patients with Metabolic Syndrome

Aims for the study:

  • To evaluate the prognostic values of LIVERFASt as a noninvasive biomarker in detecting hepatic steatosis in chronic hepatitis B
  •  To correlate LIVERFASt steatosis with Fibroscan Controlled Attenuation Parameter (CAP) scores

Let’s Keep in Touch!

Submit your email below to receive email updates
on events, new product releases and more!

For further inquiry, please contact us at: service@fibronostics.com
For clinical and medical enquiries, contact us at: medicalaffairs@fibronostics.com